NOX-E36 ( DrugBank: - )


1 disease
告示番号疾患名(ページ内リンク)臨床試験数
49全身性エリテマトーデス1

49. 全身性エリテマトーデス


臨床試験数 : 993 薬物数 : 702 - (DrugBank : 184) / 標的遺伝子数 : 116 - 標的パスウェイ数 : 200
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT00976729
(ClinicalTrials.gov)
May 200911/9/2009NOX-E36 First-in-Human (FIH) StudyNOX-E36 - A Phase I, Double-Blind, Placebo Controlled, Single Intravenous and Subcutaneous Dose, Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Study in Healthy SubjectsChronic Inflammatory Diseases;Type 2 Diabetes Mellitus;Systemic Lupus ErythematosusDrug: NOX-E36;Drug: PlaceboNOXXON Pharma AGNULLCompleted18 Years60 YearsBoth72Phase 1United Kingdom